Literature DB >> 953032

Purification of urokinase by affinity chromatography.

L Holmberg, B Bladh, B Astedt.   

Abstract

Commercially available urokinase (EC 3.4.99.26), though highly active, is still contaminated with unrelated proteins and degradation fragments of urokinase. Further purification of a urokinase preparation by chromatography on benzamidine-Sepharose is described. The final preparation consisted of two molecular forms of urokinase with molecular weights of respectively 31 000 and 54 000. The 54 000-dalton urokinase appears to be composed of two protein chains, one of which is the 31 000-dalton urokinase. A monospecific antiserum against urokinase was raised.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 953032     DOI: 10.1016/0005-2744(76)90174-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

1.  Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.

Authors:  J I Weitz; B Leslie
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

2.  Release of plasminogen activator from normal and neoplastic endometrium.

Authors:  L Svanberg; B Astedt
Journal:  Experientia       Date:  1979-06-15

3.  Some characteristics of urokinase released in organ culture of human kidney.

Authors:  B Astedt; B Bladh; L Holmberg
Journal:  Experientia       Date:  1977-05-15

4.  Expression in Escherichia coli of biologically active enzyme by a DNA sequence coding for the human plasminogen activator urokinase.

Authors:  B Ratzkin; S G Lee; W J Schrenk; R Roychoudhury; M Chen; T A Hamilton; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

5.  Adjuvant treatment of ovarian carcinoma with tranexamic acid.

Authors:  B Astedt
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

6.  Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation.

Authors:  H A Chapman; O L Stone; Z Vavrin
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

7.  Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.

Authors:  A Kjaeldgaard; B Larsson; B Astedt
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

8.  Immunological characterisation of plasminogen activators in the human vessel wall.

Authors:  H Ljungnér; L Holmberg; A Kjeldgaard; I M Nilsson; B Astedt
Journal:  J Clin Pathol       Date:  1983-09       Impact factor: 3.411

9.  Complex-formation and inhibition of urokinase by blood plasma proteins.

Authors:  E K Waller; W D Schleuning; E Reich
Journal:  Biochem J       Date:  1983-10-01       Impact factor: 3.857

10.  Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.

Authors:  D A Waltz; L Z Sailor; H A Chapman
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.